SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune is trending as the community keenly anticipates 48-week IMPACT Phase 2b trial data for its MASH treatment, Pemvidutide, following reports of improved antifibrotic activity and favorable tolerability. Excitement is high around the FDA's support for advancing to a Phase 3 trial and the integration of AI-assisted pathology reads, driving intense speculation about potential strategic partnerships or acquisitions.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending lower following its recent financial results, which highlighted weak demand in the crucial China market and concerns over gross margin compression. Community discussion centers on whether the brand is losing appeal to younger consumers amidst rising competition and questions around management's strategy, with some viewing the dip as a buying opportunity while others express long-term skepticism.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as investors hotly debate a lawsuit filed against alleged manipulators, with strong opinions on whether management is effectively addressing stock undervaluation through promised buybacks. The community discussion also centers on the phased rollout of a large AI data center contract and a recent Nobel Sustainability Trust nomination, as many question market integrity and management's actions amidst persistent share price pressure.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata (INOD) is gaining significant attention as investors keenly anticipate a transformative strategic partnership, potentially with a major government or military contractor, expected to be announced before year-end. While bulls are confident in a substantial rally from current oversold conditions, citing INOD's strong fundamentals in the booming AI data training sector, skeptics voice concerns over past delays and the stock's ability to overcome broader market headwinds and institutional buying limitations.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is actively discussed following the executive order to reclassify cannabis to Schedule III, a significant policy shift that the company is leveraging to advance its U.S. medical cannabis operations through its newly formed Tilray Medical USA unit. Despite sector-wide volatility interpreted by some as a "sell the news" event, many in the community emphasize the long-term benefits for profitability and institutional investment stemming from this historic regulatory change.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as new developments in its autonomous driving technology, including an in-house AI chip and expanded hands-free driving capabilities, are re-energizing investor conversation. The community is actively discussing how these advancements, alongside the anticipated R2 vehicle, position Rivian as a significant player evolving beyond a traditional EV manufacturer, fueling expectations of substantial growth.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale Power is experiencing significant volatility driven by an upcoming shareholder vote on increasing authorized shares, fueling concerns about potential dilution, and a major investor's planned divestment. Despite its unique NRC-certified SMR technology being touted as crucial for AI's immense energy demands, community sentiment remains sharply divided between those labeling it a "scam" due to recent declines and others seeing a "generational buying opportunity" in the long-term nuclear power narrative.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is actively trending following a stronger-than-expected fiscal Q4 earnings report, driven by increasing optimism around its potential to capitalize on significant data center energy opportunities. The community is buzzing with speculation about FCEL becoming a prominent "AI energy play," highlighting its natural gas-fueled solutions as a timely answer to powering the surging demands of digital infrastructure. While some investors express long-term profit skepticism, the narrative of improving technology and substantial market potential is driving active discussion and interest.

FedEx Corp. is a holding company, which engages in the provision of transportation, e-commerce, business services, and business solutions. It operates through the following segments: FedEx Express, FedEx Freight, Corporate, Other, and Eliminations. The FedEx Express segment offers transportation and delivery services. The FedEx Freight segment refers to freight transportation services to business and residences. The FedEx Services segment includes sales, marketing, information technology, communications, customer service, technical support, billing and collection services, and certain back-office functions that support the company's operating segments. The Corporate, Other, and Eliminations segment is involved in the corporate headquarters costs for executive officers and certain legal and finance functions, as well as certain other costs and credits not attributed to the firm's core business. The company was founded by Frederick Wallace Smith on June 18, 1971, and is headquartered in Memphis, TN.

Fedex Corp

FedEx is trending following stronger-than-expected financial results, driven by ongoing cost-cutting and network transformation initiatives. The community is actively debating the significance of the earnings beat and raised outlook, with bulls anticipating further upside, while others express caution regarding potential impacts from expiring trade exemptions and fierce industry competition. The immediate market reaction has been a key talking point, with some noting limited sustained gains despite the positive report.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is trending following its significant acquisition of Cidara Therapeutics for an experimental flu drug, a strategic move reinforcing its pipeline beyond Keytruda. This development, coupled with multiple FDA fast-track designations and positive clinical data for other assets, has the community buzzing about Merck's robust future growth trajectory and increasing portfolio diversification.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Montecito Bank & Trust Invests $3.23 Million in Johnson & Johnson $JNJ

Montecito Bank & Trust bought a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm...

Johnson & Johnson $JNJ Shares Bought by Czech National Bank

Czech National Bank grew its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 4.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission...

Johnson & Johnson $JNJ Shares Sold by Chesley Taft & Associates LLC

Chesley Taft & Associates LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.6% during the 3rd quarter, according to its most recent 13F filing with the Securities...

J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant

JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.

3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment

J&J, ImmunityBio and Foghorn Therapeutics stand out as oncology players amid rapid innovation in cancer care with advancing pipelines, approvals and partnerships.

U.S. FDA Approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE (lazertinib)

U.S. FDA Approval of RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE...

<ul class="summary-bullets"><li>The talks follow the administration’s push to lower U.S. drug prices using trade and regulatory leverage.</li><li>Pfizer and AstraZeneca have already reached agreements, while several other major drugmakers are still weighing potential deals.</li><li>Novartis and Roche have highlighted U.S. investment and manufacturing commitments.</li></ul><p>Novartis' U.S.-listed stock rose on Wednesday as investors weighed reports of impending U.S. drug pricing deals tied to the company.</p><p>The announcement is expected as soon as Friday and could include Roche, though details are still being finalized and additional drugmakers may be added, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-17/novartis-roche-near-us-drug-price-deal-in-easing-of-swiss-trade-tensions">report</a> by Bloomberg.</p><h2 class="st-heading-2"><strong>Trump’s Push On Drug Prices</strong></h2><p>In August,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-turns-up-heat-on-big-pharma-ce-os-to-slash-drug-prices-within-60-days-but-retail-traders-don-t-flinch/chr3jLYRdGW">Trump sent letters to 17 pharmaceutical companies</a> demanding that they cut prices for U.S. government insurance programs and align domestic pricing more closely with what patients pay in other developed countries. The letters also called for companies to make medicines available through a Trump-branded direct-to-consumer platform and commit to not charging Americans more than foreign markets under a “most-favored-nation” pricing framework.</p><p>In exchange, companies were offered multiyear relief from threatened tariffs and some potential regulatory measures. The administration has said it is using trade policy as leverage to force price reductions, arguing that Americans pay more than triple what patients in other developed nations pay for the same drugs.</p><h2 class="st-heading-2"><strong>Who Has And Hasn’t Cut Deals</strong></h2><p>Pfizer and AstraZeneca have already struck agreements with the administration in recent months, but many other drugmakers are still on the sidelines. Companies such as AbbVie, Bristol-Myers Squibb, Gilead Sciences, Amgen, Johnson &amp; Johnson, Merck, Regeneron Pharmaceuticals and Sanofi have yet to announce any deals.</p><p>Novartis said in a statement to Bloomberg it is in talks with the administration and is committed to lowering U.S. drug costs while addressing price gaps with other developed countries. Meanwhile, Roche’s Genentech unit said it supports efforts to reduce U.S. prices while urging other nations to better reward biopharmaceutical innovation.</p><p>The White House cautioned that no deal is final. “Until officially announced by President Trump or the Administration, any reporting about potential dealmaking is speculation,” spokesman Kush Desai told the news outlet.</p><h2 class="st-heading-2"><strong>Manufacturing Commitments&nbsp;</strong></h2><p>Domestic manufacturing has played a central role in negotiations. Novartis has stepped up its U.S. footprint, with CEO Vas Narasimhan recently attending the opening of a new manufacturing facility in North Carolina alongside FDA Commissioner Marty Makary.</p><p>The company plans to invest $23 billion in the U.S. over the next five years and generate about 41% of its revenue from the market, led by drugs such as Entresto. Roche has also committed to expanding in the U.S., pledging $50 billion in investment and deriving nearly half of its revenue from the country, driven by treatments including Ocrevus and Tecentriq.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for Novartis was ‘bearish’ with ‘low’ message volume, while Roche was ‘bullish’ amid ‘high’ message volume.</p><p>So far this year,&nbsp;<a href="https://stocktwits.com/symbol/NVS">Novartis’ U.S.-listed shares</a> have risen 42%, while&nbsp;<a href="https://stocktwits.com/symbol/RHHBY">Roche’s U.S.-listed stock</a> has also gained 45% over the same period.</p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Novartis company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Equity

Medical Stocks To Research - December 17th

Eli Lilly and Company, UnitedHealth Group, Pfizer, Johnson & Johnson, Boston Scientific, Thermo Fisher Scientific, and AbbVie are the seven Medical stocks to watch today, according to MarketBeat's...

Best Healthcare Stocks To Research - December 17th

UnitedHealth Group, Johnson & Johnson, and Intuitive Surgical are the three Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of publicly...

Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?

Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Up more than 2%

Up 0–2%

Flat to down 2%

Down more than 2%

The S&P 500 is modestly lower so far in December, putting the Santa Claus rally in question. The Santa Claus rally refers to the market’s tendency to rise in the final weeks of the year—what do you expect from December 16 through December 31?

What do you expect the S&amp;P 500’s total return to be in the second half of December?

Stocktwits

What do you expect the S&P 500’s total return to be in the second half of December?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$2.53	--	--	N/A
Q3 '25	$2.76	$2.80	1.54%	BEAT
Q2 '25	$2.68	$2.77	3.29%	BEAT
Q1 '25	$2.58	$2.77	7.34%	BEAT
Q4 '24	$1.99	$2.04	2.43%	BEAT

JNJ
Johnson & Johnson

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest JNJ News

JNJJohnson & Johnson